Suppliers and packagers for APRETUDE

APRETUDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499	NDA	ViiV Healthcare Company	49702-264-23	1 KIT in 1 CARTON (49702-264-23) * 3 mL in 1 VIAL (49702-238-03)	2021-12-20
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499	NDA	ViiV Healthcare Company	49702-280-63	1 KIT in 1 CARTON (49702-280-63) * 3 mL in 1 VIAL (49702-238-61)	2024-03-31

Aprepitant Suppliers and Patent Landscape

Last updated: February 19, 2026

Aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist used for the prevention of chemotherapy-induced nausea and vomiting (CINV), faces a dynamic supply chain influenced by patent expirations and generic competition. Key suppliers of aprepitant active pharmaceutical ingredient (API) and finished dosage forms are emerging, particularly as primary patents lapse. This analysis identifies leading manufacturers, assesses their market presence, and outlines the patent landscape affecting future supply.

Who are the Primary Suppliers of Aprepitant API and Finished Products?

The market for aprepitant API and finished drug products is characterized by a mix of originator manufacturers and a growing number of generic producers. The transition from a patented monopoly to a competitive generic environment has led to increased sourcing options.

Key API Manufacturers

Several companies specialize in the synthesis and supply of aprepitant API. These manufacturers are critical to the accessibility of both branded and generic formulations.

• Merck & Co., Inc. (MSD): As the originator of aprepitant (Emend®), Merck was the primary supplier of the API during the patent-protected period. While still a significant player, its API production is now primarily for its branded product and potentially through licensing agreements.
• Teva Pharmaceutical Industries Ltd.: A major generic pharmaceutical company, Teva is a significant producer and supplier of aprepitant API. Teva was one of the earliest generic entrants, necessitating robust API manufacturing capabilities.
• Dr. Reddy's Laboratories: This Indian multinational pharmaceutical company is a prominent supplier of various APIs, including aprepitant. Its involvement reflects the increasing role of Indian manufacturers in the global API market.
• Sun Pharmaceutical Industries Ltd.: Another leading Indian pharmaceutical company, Sun Pharma, manufactures and supplies aprepitant API. Its broad portfolio of generic APIs positions it as a key player.
• Lupin Limited: Lupin is actively engaged in the development and manufacturing of generic APIs. Aprepitant is part of its API offerings, catering to the global market's demand for cost-effective alternatives.
• Torrent Pharmaceuticals: This Indian company also produces and supplies aprepitant API, contributing to the competitive pricing and availability of the drug.
• Hetero Drugs Limited: Known for its extensive API manufacturing capabilities, Hetero Drugs is a supplier of aprepitant, supporting generic drug formulations.
• Mylan N.V. (now Viatris): Mylan, prior to its merger with Pfizer's Upjohn division to form Viatris, was a significant generic API manufacturer. Aprepitant is among its product offerings, contributing to global supply.
• Accord Healthcare: While often focusing on finished dosage forms, Accord Healthcare, like many generic companies, may source API from its own integrated manufacturing or from third-party suppliers, potentially including aprepitant.

The capacity and regulatory compliance (e.g., US FDA, EMA) of these API manufacturers are crucial for the quality and market accessibility of generic aprepitant products.

Key Finished Dosage Form Manufacturers

These companies formulate and market finished aprepitant products, including oral capsules and intravenous formulations.

• Merck & Co., Inc. (MSD): Markets branded Emend® (oral capsules and intravenous form: fosaprepitant).
• Teva Pharmaceutical Industries Ltd.: Offers generic aprepitant capsules.
• Dr. Reddy's Laboratories: Manufactures and markets generic aprepitant capsules.
• Sun Pharmaceutical Industries Ltd.: Provides generic aprepitant capsules.
• Viatris Inc.: Markets generic aprepitant products.
• Accord Healthcare: Offers generic aprepitant capsules and may have intravenous formulations.
• Aurobindo Pharma: A significant global generic manufacturer, Aurobindo provides generic aprepitant capsules.
• Cipla Limited: Another major Indian pharmaceutical company, Cipla, offers generic aprepitant capsules.
• Hikma Pharmaceuticals PLC: This global pharmaceutical company manufactures and markets a range of generic injectable and oral medications, including aprepitant.

The production of intravenous formulations, often using the prodrug fosaprepitant, is undertaken by a subset of these companies, requiring specialized sterile manufacturing facilities.

What is the Patent Landscape for Aprepitant?

The patent landscape for aprepitant has significantly evolved from its originator-led exclusivity to a more competitive generic environment. Understanding these patent timelines is critical for assessing market entry and potential litigation.

Key Patents and Expirations

The primary patent protecting the aprepitant molecule and its therapeutic use has expired in major markets, paving the way for generic competition.

• U.S. Patent No. 5,719,147: This is a foundational patent covering aprepitant and related compounds. It was granted on February 17, 1998.
  • Term: Initially set to expire in November 2015, but was extended by the U.S. Patent and Trademark Office (USPTO) due to regulatory delays. The effective expiration date, considering extensions and potential challenges, is key.
  • Generic Entry: Generic versions of oral aprepitant became available in the U.S. following the expiration or successful challenge of this patent and any subsequent formulation or method-of-use patents.
• U.S. Patent No. 6,214,841: This patent relates to pharmaceutical compositions containing aprepitant.
  • Term: Expiration dates for such patents also influence generic market entry.
• U.S. Patent No. 6,593,318: This patent covers methods of treating nausea and vomiting using aprepitant.
  • Term: Similar to other composition and method patents, its expiration date is crucial for determining the scope of generic availability.
• European Patents: Corresponding patents in Europe also expired, allowing for generic market entry across various European Union member states. The Unitary Patent system may offer different considerations for future patent protection within participating countries.

Hatch-Waxman Act and Generic Competition (U.S. Context)

In the United States, the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) governs the abbreviated new drug application (ANDA) process for generic drugs.

• ANDA Process: Generic manufacturers file ANDAs to demonstrate their product is bioequivalent to the reference listed drug (RLD).
• Patent Certifications: ANDA filers must certify that the relevant patents are invalid, expired, or will not be infringed.
  • Paragraph IV Certification: This certification challenges a patent's validity or non-infringement. It triggers a 30-month stay on FDA approval if the patent holder sues for infringement, providing a window for patent litigation.
• Market Exclusivity: The first generic company to successfully challenge a patent via a Paragraph IV certification and receive tentative FDA approval is often granted 180 days of market exclusivity, significantly impacting market dynamics.

Fosaprepitant Patents

Fosaprepitant is a water-soluble prodrug of aprepitant, designed for intravenous administration. Patents related to fosaprepitant and its formulations also influence the supply of IV CINV prophylaxis.

• Formulation Patents: These patents cover specific formulations that enhance stability, solubility, or ease of administration for intravenous use.
• Method of Use Patents: Patents may cover the specific use of fosaprepitant in certain patient populations or treatment regimens.
• Generic Fosaprepitant: Generic versions of fosaprepitant have also entered the market following the expiration of key patents, further broadening treatment options.

Key Considerations for Future Supply

• Evergreening Strategies: Pharmaceutical companies may employ "evergreening" strategies by obtaining patents on new formulations, dosages, or delivery methods to extend market exclusivity beyond the primary compound patent. These can include patents on:
  • Specific polymorphic forms of the API.
  • Novel salt forms.
  • Modified-release formulations.
  • Combination therapies.
• Patent Litigation: Ongoing or potential patent litigation related to secondary patents can create uncertainty for generic manufacturers and impact market entry timelines.
• Regulatory Approvals: The pace of regulatory approvals for generic aprepitant products in different regions (FDA, EMA, PMDA, etc.) directly affects supply availability.

The expiration of key patents has fundamentally reshaped the aprepitant market, enabling a broader range of suppliers to offer generic alternatives.

What are the Regulatory and Quality Considerations for Aprepitant Suppliers?

Suppliers of aprepitant API and finished dosage forms must adhere to stringent regulatory requirements and maintain high-quality standards to ensure patient safety and product efficacy.

Good Manufacturing Practices (GMP)

• Global Standards: All manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceutical and Medical Devices Agency (PMDA) in Japan.
• API Manufacturing: GMP compliance for API production includes stringent controls over raw materials, synthesis processes, purification, impurity profiling, and stability testing. Facilities are subject to regular inspections.
• Finished Product Manufacturing: GMP for finished products encompasses formulation, tableting/encapsulation, sterile processing (for intravenous products), packaging, labeling, and quality control testing.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

• DMFs (U.S.): API manufacturers typically submit Drug Master Files to the FDA. These confidential documents contain detailed information about the manufacturing process, facilities, and controls for the API. Generic drug applicants reference these DMFs in their ANDAs.
• CEPs (Europe): In Europe, manufacturers may obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP demonstrates that the API complies with the relevant European Pharmacopoeia monograph, streamlining the regulatory review process for Marketing Authorisation Applications (MAAs).

Impurity Profiling and Control

• ICH Guidelines: Suppliers must adhere to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q3A (Impurities in New Drug Substances) and Q3B (Impurities in New Drug Products).
• Genotoxic Impurities: Identification and control of potentially genotoxic impurities are critical, especially those that may arise from synthetic routes.
• Stability Studies: Comprehensive stability studies are required to establish shelf-life and storage conditions for both API and finished products under various climatic zones.

Site Inspections and Audits

• Regulatory Inspections: FDA, EMA, and other national regulatory bodies conduct periodic inspections of manufacturing sites to ensure ongoing GMP compliance.
• Customer Audits: Finished product manufacturers frequently audit their API suppliers to verify quality systems and manufacturing capabilities.

Supply Chain Security and Traceability

• Counterfeit Prevention: Robust measures are necessary to prevent counterfeiting and ensure the integrity of the supply chain from API production to the patient.
• Track and Trace: Regulations like the U.S. Drug Supply Chain Security Act (DSCSA) mandate product tracing capabilities, requiring serialization and data exchange throughout the supply chain.

The selection of aprepitant suppliers hinges on their ability to consistently meet these rigorous regulatory and quality benchmarks. A supplier's track record of successful inspections and adherence to international pharmacopoeial standards is a critical due diligence factor.

What is the Global Market Size and Growth Outlook for Aprepitant?

The global aprepitant market is influenced by the increasing incidence of chemotherapy use, particularly for cancer treatments, and the expanding access to generic formulations.

Market Drivers

• Cancer Treatment Growth: The rising global cancer burden and the subsequent increase in the use of chemotherapy are primary drivers for antiemetic drugs like aprepitant. The World Health Organization projects a significant increase in cancer incidence globally.
• Generic Availability: The expiration of key patents has led to the introduction of multiple generic aprepitant products, increasing affordability and accessibility, especially in emerging markets. This competition has driven down prices, expanding the overall market volume.
• Supportive Care in Oncology: Aprepitant is a standard component of supportive care in oncology, improving patient compliance and quality of life during treatment. Guidelines from organizations like the National Comprehensive Cancer Network (NCCN) recommend its use.
• Intravenous Formulations: The availability of intravenous fosaprepitant provides an alternative for patients unable to take oral medications, further expanding the treatment scope.

Market Challenges

• Competition from Other Anti-emetics: Aprepitant competes with other classes of antiemetics, including 5-HT3 receptor antagonists (e.g., ondansetron, granisetron) and other NK1 receptor antagonists.
• Pricing Pressures: Intense generic competition exerts significant downward pressure on pricing, impacting revenue for all market participants.
• Reimbursement Policies: Variations in reimbursement policies across different healthcare systems can affect patient access and physician prescribing patterns.

Market Size and Projections

• Historical Growth: The market for aprepitant and its prodrugs has shown consistent growth driven by the factors mentioned above. Before patent expiry, the market was dominated by branded Emend®.
• Post-Patent Expiry Impact: Following generic entry, the market value may have seen initial disruption due to price erosion. However, increased volume and market penetration in previously underserved regions can lead to overall volume growth. Precise market size figures are proprietary and vary by market research firm. Estimates for the global antiemetic market, which includes aprepitant, are in the billions of dollars, with NK1 antagonists forming a significant segment.
• Growth Rate: The market is projected to continue growing at a compound annual growth rate (CAGR) of approximately 4-7% in the coming years, driven by increasing chemotherapy cycles and wider generic adoption.

The availability of multiple suppliers for both API and finished products ensures a competitive market that is expected to expand, particularly in developing economies where access to advanced cancer supportive care is growing.

Key Takeaways

• Merck & Co. is the originator of aprepitant, but the market now features numerous generic API and finished product manufacturers, including Teva, Dr. Reddy's, Sun Pharma, Viatris, and Accord Healthcare.
• The patent landscape is dominated by the expiration of foundational patents (e.g., U.S. Patent No. 5,719,147), which has enabled widespread generic competition. Secondary patents and potential evergreening strategies remain points of interest.
• Suppliers must comply with stringent global GMP regulations, ICH guidelines for impurity control, and possess DMFs or CEPs for regulatory approval.
• The global aprepitant market is driven by increasing cancer treatment rates and the affordability of generic options, with projections indicating continued growth, albeit with significant pricing pressure due to competition.

FAQs

1. What is the difference between aprepitant and fosaprepitant? Aprepitant is the active substance that blocks the NK1 receptor. Fosaprepitant is a water-soluble prodrug of aprepitant, administered intravenously, which is converted to aprepitant in the body.

2. Which regulatory bodies oversee aprepitant API manufacturing? Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national agencies in other major markets such as Japan's PMDA and India's Central Drugs Standard Control Organisation (CDSCO).

3. How does the Hatch-Waxman Act impact aprepitant supply? The Hatch-Waxman Act facilitates the approval of generic drugs by allowing abbreviated new drug applications (ANDAs). It also includes provisions for patent challenges (Paragraph IV certifications) and periods of market exclusivity for the first generic entrant, significantly influencing the timeline and nature of aprepitant market competition.

4. What are the primary indications for aprepitant? Aprepitant is primarily indicated for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, and for the prevention of postoperative nausea and vomiting.

5. Are there any known shortages of aprepitant or fosaprepitant? Specific shortage information can vary by region and time. Manufacturers and regulatory agencies like the FDA's Drug Shortages list should be monitored for current availability status. The broad supplier base generally mitigates widespread, prolonged shortages.

Citations

[1] U.S. Patent No. 5,719,147. (1998). Substituted 2H-1,2-diaminopyrazoles and related compounds. United States Patent and Trademark Office. [2] U.S. Patent No. 6,214,841. (2001). Pharmaceutical compositions containing aryl-alkyl amides. United States Patent and Trademark Office. [3] U.S. Patent No. 6,593,318. (2003). Use of substituted aryl-alkyl amides to treat nausea and vomiting. United States Patent and Trademark Office. [4] Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Impurities in New Drug Substances Q3A(R2). [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline Impurities in New Drug Products Q3B(R2). [7] World Health Organization. (2020). Global cancer observatory. International Agency for Research on Cancer. [8] National Comprehensive Cancer Network. (Ongoing). NCCN Clinical Practice Guidelines in Oncology. (Specific guidelines for various cancer types and their supportive care).